Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer
Anticancer Research · 2024
DOI: 10.21873/anticanres.17165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yoshito Imamura und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, ErbB Receptors.
Abstract (Originalsprache)
BACKGROUND/AIM: Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of non-small cell lung cancer (NSCLC), but specific outcomes of ICIs treatment among patients with postoperative recurrence of NSCLC remain unclear. The objective of the study was to compare the efficacy of ICIs and chemotherapy with conventional chemotherapy only in patients with postoperative recurrence of epidermal growth factor receptor (EGFR) wild-type NSCLC. PATIENTS AND METHODS: A retrospective analysis was performed on patients who underwent anatomical lung resection at the Nagoya University Hospital and were treated for postoperative recurrence of wild-type EGFR NSCLC. This study evaluated the prognosis for postoperative recurrence, including ICIs treatment and other clinicopathological factors. RESULTS: Of the 83 patients included in the analysis, 20 patients underwent chemotherapy and 63 patients underwent chemotherapy combined with ICIs. The combination of ICIs and chemotherapy significantly prolonged survival after recurrence (median survival: 33.1 months vs. 22.0 months, p=0.01). In the ICIs group, no significant differences in survival were detected between patients with different programmed death ligand 1 (PD-L1) status (Tumor Proportion Scores:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; tkato@med.nagoya-u.ac.jp.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Zitieren
APA
Imamura, Y., Kato, T., Nomata, Y., Okado, S., Watanabe, H., Kawasumi, Y., Nakanishi, K., Kadomatsu, Y., Ueno, H., Nakamura, S., Mizuno, T., Hase, T., Tanaka, I., Ishii, M., Yatsuya, H., & Chen-Yoshikawa, T. F. (2024). Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17165
Vancouver
Imamura Y, Kato T, Nomata Y, Okado S, Watanabe H, Kawasumi Y, et al. Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.17165
BibTeX
@article{Imamura2024,
author = {Imamura, Yoshito and Kato, Taketo and Nomata, Yuji and Okado, Shoji and Watanabe, Hiroki and Kawasumi, Yuta and Nakanishi, Keita and Kadomatsu, Yuka and Ueno, Harushi and Nakamura, Shota and Mizuno, Tetsuya and Hase, Tetsunari and Tanaka, Ichidai and Ishii, Makoto and Yatsuya, Hiroshi and Chen-Yoshikawa, Toyofumi Fengshi},
title = {Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17165}
}
EUVIMED